File CTN to initiate adult hypoparathyroidism phase 3 trial in Japan
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 10 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- Q2 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“On track to file CTN to initiate adult HP phase 3 trial in Japan in the second quarter of 2021.”
What we found
Evidence strength A What the grades mean
A later 20-F says the CTN for the PaTHway Japan Trial was submitted in Q2 2021, within the deadline; PMDA acceptance followed in July 2021.
-
A Ascendis Pharma A/S 6-K filed 2021-07-06
“The Company also announced the Japanese Pharmaceuticals and Medical Devices Agency (“PMDA”) acceptance of the clinical trial notification for the PaTHway Japan Trial” ✓ confirmed on the page
-
A Ascendis Pharma A/S 20-F filed 2022-03-02
“In the second quarter of 2021, we submitted a Clinical Trial Notification (“CTN”) to the MHLW for PaTHway Japan Trial, a Phase 3 trial to evaluate the safety, tolerability, and efficacy of TransCon PTH.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- File
- Deliverable
- CTN filing for adult HP phase 3 trial in Japan
- Where
- Japan
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Ascendis Pharma A/S? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ASND-025539 · Corrections policy